2024-11-05 - Analysis Report
## AbbVie Inc (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a research-based biopharmaceutical company that develops, manufactures, and commercializes a wide range of medicines for various chronic and serious illnesses.

**1. Performance vs S&P 500 (VOO):**

* **Cumulative Return (ABBV):** 163.81%
* **Cumulative Return (VOO):** 131.78%
* **Performance Gap:** 32.03%
* **Relative Outperformance:** 72.17% (Meaning ABBV has outperformed VOO by a significant margin, ranking in the 72nd percentile of historical performance gaps)

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|---|---|---|---|---|
| 2015 | -8.5% | 30.2% | -8.9% | 1.1 |
| 2016 | 8.3% | 15.8% | -2.6% | 0.9 |
| 2017 | 51.9% | 7.2% | 33.1% | 0.8 |
| 2018 | -13.0% | 34.1% | -1.7% | 1.1 |
| 2019 | -2.2% | 27.8% | -33.2% | 0.9 |
| 2020 | 23.6% | 33.7% | 4.2% | 0.7 |
| 2021 | 39.0% | 11.6% | -2.9% | 0.6 |
| 2022 | 30.4% | 22.4% | 76.6% | 0.3 |
| 2023 | -15.8% | 19.4% | -51.3% | 0.2 |
| 2024 | 51.0% | 14.6% | 15.8% | 0.2 |

* **Analysis:** ABBV has generally shown higher returns (CAGR) than the market (VOO). However, the beta has been consistently lower than 1, indicating less volatility compared to the market. The alpha, measuring the excess return compared to the market, has been positive in some years and negative in others, highlighting periods of both outperformance and underperformance.

**2. Recent Price Action:**

* **Last Close:** 203.55
* **Last Market:** 201.98
* **5-day Moving Average:** 197.61
* **20-day Moving Average:** 192.7
* **60-day Moving Average:** 194.07

* **Analysis:** The current price is above all the moving averages, indicating a potential upward trend. The price has experienced a recent jump from 201.98 to 203.55, suggesting positive momentum.

**3. Technical Indicators:**

* **RSI:** 61.91 
* **PPO:** 0.85 
* **Delta_Previous_Relative_Divergence:** 11.54 (+)
* **Expected Return:** 1.5% (This represents the potential long-term (2 years+) excess return over S&P 500 if investing in ABBV)

* **Analysis:** 
    * The RSI is slightly above 60, indicating a potential overbought condition. 
    * The PPO is positive, suggesting an upward price momentum.
    * The positive delta in the relative divergence implies a short-term uptrend.
    * The expected return is positive, indicating a potentially favorable long-term investment outlook. 

**4. Recent Earnings & Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-30 | 3 | 2.92 |
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |

* **Analysis:** The company has consistently exceeded earnings expectations in recent quarters. This consistent positive performance suggests strong underlying business fundamentals and continued growth potential. The most recent earnings report (2024-10-30) beat expectations by a small margin, reinforcing the positive outlook.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-06-30 | $14.46B | 70.94% |
| 2024-03-31 | $12.31B | 66.74% |
| 2023-12-31 | $14.30B | 60.11% |
| 2023-09-30 | $13.93B | 53.44% |
| 2023-06-30 | $13.87B | 69.42% |

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $6.78B | 20.21% |
| 2024-03-31 | $8.01B | 17.10% |
| 2023-12-31 | $10.36B | 7.93% |
| 2023-09-30 | $12.09B | 14.70% |
| 2023-06-30 | $12.87B | 15.73% |

* **Analysis:** ABBV exhibits strong revenue and profitability growth. The profit margin and ROE have remained consistently high, suggesting sound management and efficient operations. 

**6. News & Recent Issues:**

* **Recent Earnings News:**  You can find recent earnings reports on financial news websites like Yahoo Finance, MarketWatch, or Seeking Alpha. 
* **Recent Market Outlook:** You can get recent market outlooks on financial news websites or from analysts at reputable investment firms.
* **Analyst Opinions & Performance Highlights:** Look for analyst ratings and price targets on platforms like FINBOLD, Yahoo Finance, or TipRanks. 

**7. Summary:**

ABBV has consistently demonstrated strong financial performance with high revenue and profitability growth. The company has been outperforming the S&P 500 (VOO) in recent years. While current technical indicators suggest potential overbought conditions, the long-term outlook remains positive, backed by the company's strong earnings track record, positive analyst opinions, and a favorable expected return.  Investors considering a long-term investment in the healthcare sector may find ABBV to be a strong candidate. However, it's essential to monitor the stock's performance and the overall market conditions before making an investment decision.
